Botanix Pharmaceuticals Ltd (BOT) - Total Liabilities
Based on the latest financial reports, Botanix Pharmaceuticals Ltd (BOT) has total liabilities worth AU$47.80 Million AUD (≈ $33.82 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BOT long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Botanix Pharmaceuticals Ltd - Total Liabilities Trend (1989–2025)
This chart illustrates how Botanix Pharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Botanix Pharmaceuticals Ltd balance sheet assets.
Botanix Pharmaceuticals Ltd Competitors by Total Liabilities
The table below lists competitors of Botanix Pharmaceuticals Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Maskapai Reasuransi Indonesia
JK:MREI
|
Indonesia | Rp3.81 Trillion |
|
Jian Sin Industrial Co Ltd
TWO:4502
|
Taiwan | NT$1.74 Billion |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr3.96 Million |
|
Sangshin Electronics Co. Ltd
KQ:263810
|
Korea | ₩39.13 Billion |
|
Porn Prom Metal Public Company Limited
BK:PPM
|
Thailand | ฿947.43 Million |
|
Korea Eng Cons
KO:023350
|
Korea | ₩270.72 Billion |
|
Namibia Critical Metals Inc
V:NMI
|
Canada | CA$1.33 Million |
|
Petratherm Ltd
AU:PTR
|
Australia | AU$466.42K |
Liability Composition Analysis (1989–2025)
This chart breaks down Botanix Pharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Botanix Pharmaceuticals Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Botanix Pharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Botanix Pharmaceuticals Ltd (1989–2025)
The table below shows the annual total liabilities of Botanix Pharmaceuticals Ltd from 1989 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$47.80 Million ≈ $33.82 Million |
+1180.69% |
| 2024-06-30 | AU$3.73 Million ≈ $2.64 Million |
+97.99% |
| 2023-06-30 | AU$1.88 Million ≈ $1.33 Million |
-67.97% |
| 2022-06-30 | AU$5.89 Million ≈ $4.16 Million |
+411.76% |
| 2021-06-30 | AU$1.15 Million ≈ $813.76K |
-31.31% |
| 2020-06-30 | AU$1.67 Million ≈ $1.18 Million |
-63.48% |
| 2019-06-30 | AU$4.58 Million ≈ $3.24 Million |
+221.60% |
| 2018-06-30 | AU$1.43 Million ≈ $1.01 Million |
+202.93% |
| 2017-06-30 | AU$470.60K ≈ $332.98K |
-8.77% |
| 2016-06-30 | AU$515.83K ≈ $364.98K |
+463.23% |
| 2015-06-30 | AU$91.58K ≈ $64.80K |
-70.44% |
| 2014-06-30 | AU$309.85K ≈ $219.24K |
-87.65% |
| 2013-06-30 | AU$2.51 Million ≈ $1.78 Million |
+6.71% |
| 2012-06-30 | AU$2.35 Million ≈ $1.66 Million |
+3.42% |
| 2011-06-30 | AU$2.27 Million ≈ $1.61 Million |
+22.57% |
| 2010-06-30 | AU$1.86 Million ≈ $1.31 Million |
+62.88% |
| 2009-06-30 | AU$1.14 Million ≈ $805.90K |
+5.28% |
| 2008-06-30 | AU$1.08 Million ≈ $765.47K |
+79.27% |
| 2007-06-30 | AU$603.47K ≈ $427.00K |
+112.57% |
| 2006-06-30 | AU$283.89K ≈ $200.87K |
+27.17% |
| 2005-06-30 | AU$223.25K ≈ $157.96K |
+22.92% |
| 2004-06-30 | AU$181.62K ≈ $128.50K |
-37.22% |
| 2003-06-30 | AU$289.29K ≈ $204.69K |
-36.82% |
| 2002-06-30 | AU$457.88K ≈ $323.98K |
+170.40% |
| 2001-06-30 | AU$169.34K ≈ $119.82K |
+43.51% |
| 2000-06-30 | AU$118.00K ≈ $83.49K |
-98.54% |
| 1999-06-30 | AU$8.06 Million ≈ $5.71 Million |
-44.80% |
| 1998-06-30 | AU$14.61 Million ≈ $10.34 Million |
-19.80% |
| 1997-06-30 | AU$18.22 Million ≈ $12.89 Million |
-4.79% |
| 1996-06-30 | AU$19.13 Million ≈ $13.54 Million |
-35.62% |
| 1995-06-30 | AU$29.72 Million ≈ $21.03 Million |
+31.96% |
| 1994-06-30 | AU$22.52 Million ≈ $15.94 Million |
+14.41% |
| 1993-06-30 | AU$19.68 Million ≈ $13.93 Million |
+35.61% |
| 1992-06-30 | AU$14.52 Million ≈ $10.27 Million |
-0.16% |
| 1991-06-30 | AU$14.54 Million ≈ $10.29 Million |
+6.72% |
| 1990-06-30 | AU$13.62 Million ≈ $9.64 Million |
+15.26% |
| 1989-06-30 | AU$11.82 Million ≈ $8.36 Million |
-- |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment o… Read more